[go: up one dir, main page]

TW201615217A - 抗生素藥物臨床新應用 - Google Patents

抗生素藥物臨床新應用 Download PDF

Info

Publication number
TW201615217A
TW201615217A TW104134908A TW104134908A TW201615217A TW 201615217 A TW201615217 A TW 201615217A TW 104134908 A TW104134908 A TW 104134908A TW 104134908 A TW104134908 A TW 104134908A TW 201615217 A TW201615217 A TW 201615217A
Authority
TW
Taiwan
Prior art keywords
hcl
antibiotic
hydrochloride
group
cancer
Prior art date
Application number
TW104134908A
Other languages
English (en)
Other versions
TWI672150B (zh
Inventor
陳丘泓
莊秀美
蕭乃文
梁瑞岳
筱彤 陳
Original Assignee
朗齊生物醫學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55760314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201615217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 朗齊生物醫學股份有限公司 filed Critical 朗齊生物醫學股份有限公司
Publication of TW201615217A publication Critical patent/TW201615217A/zh
Application granted granted Critical
Publication of TWI672150B publication Critical patent/TWI672150B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

本發明提供多種抗生素藥物的新臨床之應用。該多種抗生素藥物皆是經過衛生署通過核准上市的抗生素藥物。本發明提供多種抗生素藥物有效的抑制不同類型的癌細胞。

Description

抗生素藥物臨床新應用
本發明係為多種抗生素藥物的新適應症之應用，尤其該多種藥物為通過臨床實驗且具有抑制多種癌症之用途。
癌症長期高居全球死因之首，且罹患癌症人數更是逐年攀升，因此治療癌症儼然成為重要的課題。癌症的治療可區分為手術治療、放射線治療、化學治療及標靶治療。
一般來說，癌症藥物治療無論是化學治療或標靶治療，目的多是讓癌細胞無法複製、分裂，來阻斷腫瘤的蔓延擴張。在臨床治療選擇上，通常會結合一到數種化療藥物以及標靶治療，希望能藉由不同機制來殺死癌細胞以提高治療效果，但事實上，還是常遇到患者對於治療藥物的反應不佳。進一步，許多癌細胞相繼產生抗藥性，使藥物的使用成效大幅降低，最終導致癌症治療失敗。
抗生素(英語：antibiotic)由微生物(包括細菌、真菌、放線菌屬)所產生的具有抑制其它類微生物生長、生存的一類次級代謝產物，以及用化學方法合成或半合成的類似化合物。在 定義上是一較廣的概念，包括抗細菌抗生素、抗真菌抗生素以及對付其他微小病原之抗生素；但臨床實務中，抗生素常常是指抗細菌抗生素。
發明人依據長年的研究經驗，人類的癌症細胞常常 有與正常細胞具有不同的表現性狀，型態上的差異或是作用機轉的變化或許也有可能被視為一種外來的侵入者，而每一種癌症細胞所在的位置不同，變異的狀態又與所處的環境有關，因此，第一個提出使用抗生素藥物抑制癌症細胞的發明概念並且進行實驗。
相對的，在這些已經使用數十年抗生素，是早已被 FDA所認可的用藥，具有大量藥物機轉及人體研究成果資料，因此，若應用在癌症方面，這項新發展會更省時、減少成本，也能和其他治療方式結合來提高效果。
在發明人提出美國臨時申請案之後，亦有其他的教 授深入研究探討其可能性，近期亦陸續有相關的研究提出並證實發明人的發明內容，該教授根據內共生理論(Endosymbiotic Theory)提出相類似的假設，意即粒線體曾經是細菌，後來被大型細菌併吞後，在其細胞內與之共生，因此粒線體和一般細胞結構不太一樣，它有自己的基因，和原核生物(如細菌)比較接近。這種差異就也許就能被設計成像標靶治療一樣，單獨抑制癌症細胞的治療。
儘管如此，藥物開發依然是重要的醫學議題，必須經過繁複的臨床前試驗才能進入臨床試驗，根據統計，平均每一萬個新藥約只有五個能夠進入第一期臨床試驗。此外，除了藥物本身是否能大量製造的難題外，還需克服藥物安全性、病人篩選、試用劑量等問題，即便藥物已經通過FDA的核准並上市，亦有可能因上市後於人體發現不良反應而強制下架回收，由此可見藥物開發具有一定的困難程度。
為解決上述的問題，本發明係針對通過臨床實驗的多種藥物進行新適應症的研發，而達到老藥新用的目標。
經過實驗設計結果顯示抗生素藥物對正常細胞沒有或僅有微小的毒性，但至於抗生素在正常細胞與腫瘤細胞之間是否具有選擇性的影響，還待更多的研究釐清，而且並非所有的抗生素在相同的條件下均能有效的抑制腫瘤細胞，需要有許多的問題進行克服。
名詞定義
抗生素依據藥物的結構可以分為九大類，包含胺基配糖體抗生素、抗黴菌劑抗生素、頭孢子菌類抗生素、β-丙醯胺抗生素類、氯黴素抗生素、青黴素類抗生素、紅黴素類抗生素、四環 素類抗生素，與其他類。
1. 氨基糖苷類抗生素，氨基糖苷類抗生素是具有氨基 糖與氨基環醇結構的一類抗生素，在臨床主要用於對革蘭氏陰性菌、綠膿桿菌等感染的治療。本發明中的抗生素藥物包含在本類別的有Amikacin sulfate、Amikacin hydrate、Netilmicin Sulfate。
2. 抗黴菌劑抗生素，一系列抗黴菌的抗生素。本發 明中的抗生素藥物包含在本類別的有Posaconazole、Artemisinin、Fluconazole、Ketoconazole、Voriconazole、Natamycin(Pimaricin)、Clotrimazole(Canesten)、Amphotericin B(Abelcet)、Flucytosine(Ancobon)、Amorolfine Hydrochloride、Terbinafine(Lamisil,Terbinex)、Butoconazole nitrate、Chloroxine、Bifonazole、Tioconazole、Nystatin(Mycostatin)、Miconazole nitrate、Liranaftate、Isoconazole nitrate(Travogen)、Terbinafine hydrochloride(Lamisil)、Ciclopirox ethanolamine、Caspofungin acetate、Naftifine HCl、Sertaconazole nitrate、Pyrithione zinc、Sulconazole Nitrate、Climbazole、Valnemulin HCl。
3. 頭孢子菌類抗生素，頭孢菌素，又名先鋒霉素， 是一系列屬於β內醯胺類的抗生素。與頭黴素一併細分為頭孢烯。本發明中的抗生素藥物包含在本類別的有Cefdinir(Omnicef)、 Cefoperazone(Cefobid)、Cefditoren pivoxil、Cephalexin(Cefalexin)、Cefoselis sulfate、Ceftiofur hydrochloride、Cefaclor(Ceclor)、Ceftazidime Pentahydrate、Moxalactam Disodium、Cephapirin Sodium。
4. β-丙醯胺抗生素類，β-內醯胺類抗生素(Beta-lactam antibiotic)是一種種類很廣的抗生素，其中包括青黴素及其衍生物、頭孢菌素、單醯胺環類、碳青黴烯和青黴烯類酶抑制劑等。基本上所有在其分子結構中包括β-內醯胺核的抗生素均屬於β內醯胺類抗生素。它是現有的抗生素中使用最廣泛的一類。本發明中的抗生素藥物包含在本類別的有Doripenem Hydrate、Meropenem、Aztreonam、Sulbactam、Sulbactam sodium(Unasyn)、Biapenem。
5. 氯黴素抗生素，氯黴素有著很廣泛的活躍性，能有效對抗革蘭氏陽性菌，包括大部份的抗藥性金黃色葡萄球菌、革蘭氏陰性菌及厭氧性生物。本發明中的抗生素藥物包含在本類別的有Gatifloxacin、Daptomycin、Sulfapyridine(Dagenan)、Sulfameter(Bayrena)、Chloramphenicol(Chloromycetin)。
6. 青黴素類抗生素，青黴素(Penicillin，或音譯盤尼西林)是指分子中含有青黴烷、能破壞細菌的細胞壁並在細菌細 胞的繁殖期起殺菌作用的一類抗生素，是由青黴菌中提煉出的抗生素。青黴素屬於β-內醯胺類抗生素(β-lactams),β-內醯胺類抗生素包括青黴素、頭孢菌素、碳青黴烯類、單環類、頭黴素類等。 本發明中的抗生素藥物包含在本類別的有Amoxicillin sodium(Amox)、Ampicillin sodium、Carbenicillin disodium、Dicloxacillin Sodium、Ampicillin Trihydrate、Benzylpenicillin sodium、Mezlocillin Sodium、Piperacillin Sodium。
7. 紅黴素類抗生素，紅黴素(英文：Erythromycin)是一種大環內酯類的抗生素。抗菌範圍與青黴素相似；主要用於對青黴素已經產生耐藥性的葡萄球菌、鏈球菌、腹瀉等胃腸道反應。本發明中的抗生素藥物包含在本類別的有Teicoplanin、Linezolid(Zyvox)、Erythromycin(E-Mycin)、Erythromycin Ethylsuccinate、Spiramycin、Tilmicosin、Azithromycin Dihydrate、Dirithromycin、Fidaxomicin。
8. 四環素類抗生素，一個廣效抗生素(Broad-spectrum antibiotic)藥物家族的泛稱，因其氫化並四苯母核而得名。本類藥物抗菌譜廣，對革蘭氏陰性菌、革蘭氏陽性菌、螺旋體、衣原體、立克次氏體、支原體、放線菌和阿米巴原蟲都有較強的作用。本發明中的抗生素藥物包含在本類別的有 Marbofloxacin、Moxifloxacin hydrochloride、Oxytetracycline(Terramycin)、Tigecycline、Oxytetracycline dihydrate、Tetracycline HCl、Chlortetracycline HCl、Minocycline HCl、Rolitetracycline。
9. 其他類抗生素：Norfloxacin(Norxacin)、Enoxacin (Penetrex)、Pefloxacin mesylate、Sparfloxacin、Levofloxacin(Levaquin)、Sarafloxacin HCl、Nalidixic acid(NegGram)、Lomefloxacin hydrochloride(Maxaquin)、Enrofloxacin、Clinafloxacin(PD127391)、Orbifloxacin、Clinafoxacin HCl、Piromidic Acid、Cinoxacin、Difloxacin HC、Rifabutin(Mycobutin)、Rifapentine(Priftin)、Pyrazinamide(Pyrazinoic acid amide)、Rifampin(Rifadin,Rimactane)、Ethionamide、Rifaximin(Xifaxan)、Protionamide(Prothionamide)、Isoniazid(Tubizid)、D-Cycloserine、Streptomycin sulfate、Clofazimine、Nitrofurazone、Sulfanilamide、Sulfadiazine、Metronidazole(Flagyl)、Sulfamethoxazole、Sulfisoxazole、Sulfamethizole(Proklar)、Sulfadimethoxine、Clindamycin phosphate、Fenbendazole(Panacur)、Sulfadoxine(Sulphadoxine)、Secnidazole(Flagentyl)、Clindamycin palmitate HCl、Clindamycin、Sulfathiazole、Trimethoprim、Sulfamerazine、Pentamidine、Colistin Sulfate(polypeptide)、toltrazuril、tinidazoleMequinol、Bacitracin、 Cetylpyridinium Chloride、Sulfaguanidine、Paromomycin Sulfate、Domiphen Bromide、Chlorquinaldol、Furaltadone HCl、Primaquine Diphosphate、Carbadox、Colistimethate Sodium、Meclocycline Sulfosalicylate、Thiostrepton、Bekanamycin、Clofoctol、Ritonavir、Entecavir hydrate、Artemisinin、Megestrol Acetate、Lansoprazole、Lopinavir(ABT-378)、Ondansetron hydrochloride、Resveratrol、Stavudine、Tenofovir Disoproxil Fumarate、Tenofovir(Viread)、Cidofovir(Vistide)、Telaprevir(VX-950)、Saxagliptin(BMS-477118,Onglyza)、Darunavir Ethanolate(Prezista)、Docosanol(Abreva)、Amprenavir(Agenerase)、Telbivudine(Sebivo,Tyzeka)、Hydrocortisone(Cortisol)、Didanosine(Videx)、Emtricitabine(Emtriva)、Lamivudine(Epivir)、Adefovir Dipivoxil(Preveon,Hepsera)、Zalcitabine、Prednisolone(Hydroretrocortine)、Nevirapine(Viramune)、Trifluridine(Viroptic)、Vidarabine(Vira-A)、Acyclovir(Aciclovir)、Albendazole Oxide(Ricobendazole)、Chenodeoxycholic acid、Valaciclovir HCl、Ganciclovir、Idoxuridine、Crystal violet、Rimantadine(Flumadine)、Taurine(organic acid)、Diclazuril(anticoccidial drug)、Rebamipide、Orphenadrine citrate(Norflex)、Terazosin HCl(Hytrin)、Lafutidine、Dextrose、BIBR-1048 (Dabigatran)、Rosuvastatin calcium(Crestor)、Ammonium Glycyrrhizinate(AMGZ)、Amfebutamone(Bupropion)、Clonidine hydrochloride(Catapres)、Fluocinolone acetonide(Flucort-N)、Loperamide hydrochloride、Mycophenolic(Mycophenolate)、Olanzapine(Zyprexa)、Racecadotril(Acetorphan)、Rosiglitazone maleate、Salbutamol sulfate(Albuterol)、Tenoxicam(Mobiflex)、Vardenafil(Vivanza)、Dopamine hydrochloride(Inotropin)、Ritodrine hydrochloride(Yutopar)、Riboflavin(Vitamin B2)、Clomipramine hydrochloride(Anafranil)、Tiotropium Bromide hydrate、Isoprenaline hydrochloride、Medroxyprogesterone acetate、Xylometazoline HCl、Phenacetin、Trazodone hydrochloride(Desyrel)、Brompheniramine、Acemetacin(Emflex)、Dabrafenib(GSK2118436)、Paroxetine HCl、Zanamivir(Relenza)、Niflumic acid、Medetomidine HCl、Diclofenac Potassium、Ulipristal、Indacaterol Maleate、Biotin(Vitamin B7)、Sodium salicylate、Methylthiouracil、Darifenacin HBr、Benztropine mesylate、Abacavir sulfate、Antipyrine、Amitriptyline HCl、Azatadine dimaleate、Triflusal、Pemirolast(BMY 26517)potassium、Homatropine Bromide、Carbimazole、Spironolactone、Ropivacaine HCl、Escitalopram oxalate、Bismuth Subcitrate Potassium(mineral)、 Chlorpropamide、Nifuroxazide、Penciclovir、Salicylanilide、Betamipron、Ethacridine lactate monohydrate(aromatic compound)、Aminothiazole、Florfenicol、Cetrimonium Bromide(antiseptic)、Thonzonium Bromide(detergent)、Pasiniazid。
本發明提供一種抗生素藥物用於製備治療癌症之用途，其中該醫藥組合物係選自由一有效劑量的一抗生素及一藥物可接受的鹽類所組成。
本發明提供一種抗病毒藥物用於製備治療癌症之用途，其中該醫藥組合物係選自由一有效劑量的一抗病毒藥物及一藥物可接受的鹽類所組成。
本發明所述之抗生素係選自由胺基配糖體抗生素、抗黴菌劑抗生素、頭孢子菌類抗生素、β-丙醯胺抗生素類、氯黴素抗生素、紅黴素類抗生素、青黴素類抗生素、四環素類抗生素及其他抗生素所組成群組之抗生素。
本發明一實施例中，其中該胺基配糖體抗生素係選自由Amikacin sulfate、Amikacin hydrate、Netilmicin Sulfate所組成之藥物。
本發明一實施例中，其中該抗黴菌劑抗生素係選自由Posaconazole、Artemisinin、Fluconazole、Ketoconazole、 Voriconazole、Natamycin(Pimaricin)、Clotrimazole(Canesten)、Amphotericin B(Abelcet)、Flucytosine(Ancobon)、Amorolfine Hydrochloride、Terbinafine(Lamisil,Terbinex)、Butoconazole nitrate、Chloroxine、Bifonazole、Tioconazole、Nystatin(Mycostatin)、Miconazole nitrate、Liranaftate、Isoconazole nitrate(Travogen)、Terbinafine hydrochloride(Lamisil)、Ciclopirox ethanolamine、Caspofungin acetate、Naftifine HCl、Sertaconazole nitrate、Pyrithione zinc、Sulconazole Nitrate、Climbazole、Valnemulin HCl所組成之藥物。
本發明一實施例中，其中頭孢子菌類抗生素係選自 由Cefdinir(Omnicef)、Cefoperazone(Cefobid)、Cefditoren pivoxil、Cephalexin(Cefalexin)、Cefoselis sulfate、Ceftiofur hydrochloride、Cefaclor(Ceclor)、Ceftazidime Pentahydrate、Moxalactam Disodium、Cephapirin Sodium所組成之藥物。
本發明一實施例中，其中β-丙醯胺抗生素係選自由 Doripenem Hydrate、Meropenem、Aztreonam、Sulbactam、Sulbactam sodium(Unasyn)、Biapenem所組成之藥物。
本發明一實施例中，其中該氯黴素抗生素係選自由 Gatifloxacin、Daptomycin、Sulfapyridine(Dagenan)、Sulfameter (Bayrena)、Chloramphenicol(Chloromycetin)所組成之藥物。
本發明一實施例中，其中該青黴素類抗生素係選自 由Amoxicillin sodium(Amox)、Ampicillin sodium、Carbenicillin disodium、Dicloxacillin Sodium、Ampicillin Trihydrate、Benzylpenicillin sodium、Mezlocillin Sodium、Piperacillin Sodium所組成之藥物。
本發明一實施例中，其中該紅黴素類抗生素係選自 由Teicoplanin、Linezolid(Zyvox)、Erythromycin(E-Mycin)、Erythromycin Ethylsuccinate、Spiramycin、Tilmicosin、Azithromycin Dihydrate、Dirithromycin、Fidaxomicin所組成之藥物。
本發明一實施例中，其中該四環素類抗生素係選自 由Marbofloxacin、Moxifloxacin hydrochloride、Oxytetracycline(Terramycin)、Tigecycline、Oxytetracycline dihydrate、Tetracycline HCl、Chlortetracycline HCl、Minocycline HCl、Rolitetracycline。所組成之藥物。
本發明一實施例中，其中該其他抗生素係選自由 Norfloxacin(Norxacin)、Enoxacin(Penetrex)、Pefloxacin mesylate、Sparfloxacin、Levofloxacin(Levaquin)、Sarafloxacin HCl、Nalidixic acid(NegGram)、Lomefloxacin hydrochloride(Maxaquin)、 Enrofloxacin、Clinafloxacin(PD127391)、Orbifloxacin、Clinafoxacin HCl、Piromidic Acid、Cinoxacin、Difloxacin HCl、ifabutin(Mycobutin)、Rifapentine(Priftin)、Pyrazinamide(Pyrazinoic acid amide)、Rifampin(Rifadin,Rimactane)、Ethionamide、Rifaximin(Xifaxan)、Protionamide(Prothionamide)、Isoniazid(Tubizid)、D-Cycloserine、Streptomycin sulfate、Clofazimine、Nitrofurazone、Sulfanilamide、Sulfadiazine、Metronidazole(Flagyl)、Sulfamethoxazole、Sulfisoxazole、Sulfamethizole(Proklar)、Sulfadimethoxine、Clindamycin phosphate、Fenbendazole(Panacur)、Sulfadoxine(Sulphadoxine)、Secnidazole(Flagentyl)、Clindamycin palmitate HCl、Clindamycin、Sulfathiazole、Trimethoprim、Sulfamerazine、Pentamidine、Colistin Sulfate(polypeptide)、toltrazuril、tinidazoleMequinol、Bacitracin、Cetylpyridinium Chloride、Sulfaguanidine、Paromomycin Sulfate、Domiphen Bromide、Chlorquinaldol、Furaltadone HCl、Primaquine Diphosphate、Carbadox、Colistimethate Sodium、Meclocycline Sulfosalicylate、Thiostrepton、Bekanamycin、Clofoctol、Ritonavir、Entecavir hydrate、Artemisinin、Megestrol Acetate、Lansoprazole、Lopinavir(ABT-378)、Ondansetron hydrochloride、Resveratrol、 Stavudine、Tenofovir Disoproxil Fumarate、Tenofovir(Viread)、Cidofovir(Vistide)、Telaprevir(VX-950)、Saxagliptin(BMS-477118,Onglyza)、Darunavir Ethanolate(Prezista)、Docosanol(Abreva)、Amprenavir(Agenerase)、Telbivudine(Sebivo,Tyzeka)、Hydrocortisone(Cortisol)、Didanosine(Videx)、Emtricitabine(Emtriva)、Lamivudine(Epivir)、Adefovir Dipivoxil(Preveon,Hepsera)、Zalcitabine、Prednisolone(Hydroretrocortine)、Nevirapine(Viramune)、Trifluridine(Viroptic)、Vidarabine(Vira-A)、Acyclovir(Aciclovir)、Albendazole Oxide(Ricobendazole)、Chenodeoxycholic acid、Valaciclovir HCl、Ganciclovir、Idoxuridine、Crystal violet、Rimantadine(Flumadine)、Taurine(organic acid)、Diclazuril(anticoccidial drug)、Rebamipide、Orphenadrine citrate(Norflex)、Terazosin HCl(Hytrin)、Lafutidine、Dextrose、BIBR-1048(Dabigatran)、Rosuvastatin calcium(Crestor)、Ammonium Glycyrrhizinate(AMGZ)、Amfebutamone(Bupropion)、Clonidine hydrochloride(Catapres)、Fluocinolone acetonide(Flucort-N)、Loperamide hydrochloride、Mycophenolic(Mycophenolate)、Olanzapine(Zyprexa)、Racecadotril(Acetorphan)、Rosiglitazone maleate、Salbutamol sulfate(Albuterol)、Tenoxicam(Mobiflex)、 Vardenafil(Vivanza)、Dopamine hydrochloride(Inotropin)、Ritodrine hydrochloride(Yutopar)、Riboflavin(Vitamin B2)、Clomipramine hydrochloride(Anafranil)、Tiotropium Bromide hydrate、Isoprenaline hydrochloride、Medroxyprogesterone acetate、Xylometazoline HCl、Phenacetin、Trazodone hydrochloride(Desyrel)、Brompheniramine、Acemetacin(Emflex)、Dabrafenib(GSK2118436)、Paroxetine HCl、Zanamivir(Relenza)、Niflumic acid、Medetomidine HCl、Diclofenac Potassium、Ulipristal、Indacaterol Maleate、Biotin(Vitamin B7)、Sodium salicylate、Methylthiouracil、Darifenacin HBr、Benztropine mesylate、Abacavir sulfate、Antipyrine、Amitriptyline HCl、Azatadine dimaleate、Triflusal、Pemirolast(BMY 26517)potassium、Homatropine Bromide、Carbimazole、Spironolactone、Ropivacaine HCl、Escitalopram oxalate、Bismuth Subcitrate Potassium(mineral)、Chlorpropamide、Nifuroxazide、Penciclovir、Salicylanilide、Betamipron、Ethacridine lactate monohydrate(aromatic compound)、Aminothiazole、Florfenicol、Cetrimonium Bromide(antiseptic)、Thonzonium Bromide(detergent)、Pasiniazid所組成之藥物。
本發明一實施例中，其中該癌症係選自由肺癌、腸道癌、大腸直腸癌、前列腺癌、膀胱癌、子宮頸癌、乳癌及血癌所 組成之群組。
本發明一實施例中，其中該藥物的有效劑量濃度為20mg/kg/day。
現今癌症藥物費用動輒上萬至數百萬元，若未來更進一步證實抗生素對腫瘤的療效，對於無法負擔昂貴治療的患者們，這些便宜而歷史悠久的藥物，會是帶來健康的新希望。
第一圖顯示本發明抗生素用藥應用於抑制癌細胞分析結果
建立細胞株
請參考表一，將不同癌症類型的細胞株進行繼代培養，計算細胞數目後，回種2*106細胞數，然後加入培養該細胞株之培養液補至體積為10ml，繼續培養2-3天。之後將細胞計數，並分裝至96孔盤，其中每孔的細胞數目固定為3000顆，且體積為100ul。
細胞存活分析方法
將96孔盤中原有的培養液吸掉，每孔加入濃度10um、體積100ul的市售藥物，放置72小時後，每孔再加入100ul已稀釋的WST-1試劑，該稀釋比例為培養液與WST-1原液的體積比為9：1，最後每個孔盤的總體積為200ul，然後將96孔盤放置於37度30~90分鐘，利用elisa reader於OD450偵測吸光值，並計算各癌症細胞株之存活率。
抗生素用藥應用於抑制癌細胞分析結果
依據細胞存活分析方法針對取得的九大類抗生素藥物，包含胺基配糖體抗生素、抗黴菌劑抗生素、頭孢子菌類抗生素、β-丙醯胺抗生素類、氯黴素抗生素、青黴素類抗生素、紅黴素類抗生素、四環素類抗生素，以及抗病毒類藥物進行測試抑制癌細胞生長的效果。
實驗結果明顯的顯示有許多的抗生素並無法有效的抑制癌症的細胞的生長(表二)。
而相對的各種的抗生素藥物分子對於各種癌症細胞 的抑制效果也不盡相同(圖一)，經過發明人實驗結果，證實抗生素藥物藥物Ritonavir、Entecavir hydrate、Posaconazole、Artemisinin、Megestrol Acetate、Fluconazole、Gatifloxacin、Ketoconazole、Lansoprazole、Acitretin、Biapenem、Cefoselis sulfate、Daptomycin、Doripenem Hydrate、Lopinavir(ABT-378)、Meropenem、Ondansetron hydrochloride(Zofran)、Resveratrol、Stavudine、Teicoplanin、Tenofovir Disoproxil Fumarate、Tenofovir(Viread)、Tigecycline、Linezolid(Zyvox)、Voriconazole、Marbofloxacin、Moxifloxacin hydrochloride、Cefaclor(Ceclor)、Cephalexin(Cefalexin)、Aztreonam(Azactam,Cayston)、Norfloxacin(Norxacin)、Cidofovir(Vistide)、Natamycin(Pimaricin)、Telaprevir(VX-950)、Saxagliptin (BMS-477118,Onglyza)、Cefdinir(Omnicef)、Clotrimazole(Canesten)、Cefoperazone(Cefobid)、Sulfapyridine(Dagenan)、Sulfameter(Bayrena)、Darunavir Ethanolate(Prezista)、Erythromycin(E-Mycin)、Amphotericin B(Abelcet)、Docosanol(Abreva)、Amprenavir(Agenerase)、Nitrofurazone(Nitrofural)、Telbivudine(Sebivo,Tyzeka)、Flucytosine(Ancobon)、Amorolfine Hydrochloride、Chloramphenicol(Chloromycetin)、Sulfanilamide、Hydrocortisone(Cortisol)、Didanosine(Videx)、Emtricitabine(Emtriva)、Lamivudine(Epivir)、Adefovir Dipivoxil(Preveon,Hepsera)、Zalcitabine、Terbinafine(Lamisil,Terbinex)、Prednisolone(Hydroretrocortine)、Rifabutin(Mycobutin)、Nevirapine(Viramune)、Enoxacin(Penetrex)、Rifapentine(Priftin)、Pyrazinamide(Pyrazinoic acid amide)、Rifampin(Rifadin,Rimactane)、Cefditoren pivoxil、Sulfadiazine、Oxytetracycline(Terramycin)、Ethionamide、Trifluridine(Viroptic)、Vidarabine(Vira-A)、Rifaximin(Xifaxan)、Acyclovir(Aciclovir)、Butoconazole nitrate、Albendazole Oxide(Ricobendazole)、Chloroxine、Chenodeoxycholic acid、Bifonazole、Pefloxacin mesylate、Valaciclovir HCl、Ganciclovir、Protionamide (Prothionamide)、Idoxuridine、Sparfloxacin、Metronidazole(Flagyl)、Tioconazole、Sulfamethoxazole、Sulfisoxazole、Crystal violet、Nystatin(Mycostatin)、Isoniazid(Tubizid)、Levofloxacin(Levaquin)、Miconazole nitrate、Sulfamethizole(Proklar)、Sulbactam、Sulphadimethoxine、Rimantadine(Flumadine)、Sarafloxacin HCl、Liranaftate、D-Cycloserine、Taurine、Diclazuril、Rebamipide、Clindamycin phosphate、Oxytetracycline dihydrate、Orphenadrine citrate(Norflex)、Terazosin HCl(Hytrin)、Lafutidine、Dextrose(D-glucose)、BIBR-1048(Dabigatran)、Rosuvastatin calcium(Crestor)、Nalidixic acid(NegGram)、Ammonium Glycyrrhizinate(AMGZ)、Amfebutamone(Bupropion)、Clonidine hydrochloride(Catapres)、Fenbendazole(Panacur)、Fluocinolone acetonide(Flucort-N)、Loperamide hydrochloride、Mycophenolic(Mycophenolate)、Olanzapine(Zyprexa)、Racecadotril(Acetorphan)、Rosiglitazone maleate、Salbutamol sulfate(Albuterol)、Sulfadoxine(Sulphadoxine)、Tenoxicam(Mobiflex)、Vardenafil(Vivanza)、Dopamine hydrochloride(Inotropin)、Ritodrine hydrochloride(Yutopar)、Isoconazole nitrate(Travogen)、Secnidazole(Flagentyl)、 Lomefloxacin hydrochloride(Maxaquin)、Riboflavin(Vitamin B2)、Clomipramine hydrochloride(Anafranil)、Ceftiofur hydrochloride、Tiotropium Bromide hydrate、Sulbactam sodium(Unasyn)、Terbinafine hydrochloride(Lamisil)、Amoxicillin sodium(Amox)、Isoprenaline hydrochloride、Medroxyprogesterone acetate、Streptomycin sulfate、Tetracycline HCl、Xylometazoline HCl、Phenacetin、Trazodone hydrochloride(Desyrel)、Brompheniramine、Clindamycin palmitate HCl、Acemetacin(Emflex)、Dabrafenib(GSK2118436)、Clindamycin、Paroxetine HCl、Zanamivir(Relenza)、Niflumic acid、Ciclopirox ethanolamine、Enrofloxacin、Medetomidine HCl、Diclofenac Potassium、Amikacin sulfate、Caspofungin acetate、Ulipristal、Indacaterol Maleate、Sulfathiazole、Amikacin hydrate、Trimethoprim、Biotin(Vitamin B7)、Sulfamerazine、Sodium salicylate、Methylthiouracil、Darifenacin HBr、Naftifine HCl、Sertaconazole nitrate、Benztropine mesylate、Abacavir sulfate、Ampicillin sodium、Antipyrine、Carbenicillin disodium、Amitriptyline HCl、Azatadine dimaleate、Triflusal、Clinafloxacin(PD127391)、Pentamidine、Pemirolast(BMY 26517)potassium、Homatropine Bromide、Colistin Sulfate、toltrazuril、 Carbimazole、Netilmicin Sulfate、Spironolactone、Ropivacaine HCl、Erythromycin Ethylsuccinate、Escitalopram oxalate、tinidazole、Pyrithione zinc、Mequinol、Spiramycin、Bismuth Subcitrate Potassium、Clofazimine、Dicloxacillin Sodium、Sulconazole Nitrate、Tilmicosin、Bacitracin、Azithromycin Dihydrate、Ampicillin Trihydrate、Orbifloxacin、Chlortetracycline HCl、Benzylpenicillin sodium、Chlorpropamide、Cetylpyridinium Chloride、Sulfaguanidine、Climbazole、Mezlocillin Sodium、Nifuroxazide、Paromomycin Sulfate、Penciclovir、Domiphen Bromide、Salicylanilide、Betamipron、Chlorquinaldol、Ethacridine lactate monohydrate、Aminothiazole、Florfenicol、Furaltadone HCl、Dirithromycin、Valnemulin HCl、Piperacillin Sodium、Minocycline HCl、Fidaxomicin、Primaquine Diphosphate、Cetrimonium Bromide、Carbadox、Ceftazidime Pentahydrate、Clinafoxacin HCl、Colistimethate Sodium、Meclocycline Sulfosalicylate、Moxalactam Disodium、Piromidic Acid、Rolitetracycline、Thiostrepton、Thonzonium Bromide、Cinoxacin、Bekanamycin、Difloxacin HCl、Cephapirin Sodium、Clofoctol、Pasiniazid等藥物對於不同的癌症細胞有明顯的抑制效果。(表三)
上列詳細說明係針對本發明之一可行實施例之具體說明，惟該實施例並非用以限制本發明之專利範圍，凡未脫離本發明技藝精神所為之等效實施或變更，均應包含於本發明之專利範圍中。
重複性實驗
依據表三所示結果，針對對癌症細胞株有效之藥物進行重覆性實驗，其結果如表四所示。
表四、具抑制癌症細胞株之抗生素

Claims (12)

  1. 一種抗生素藥物用於製備治療癌症之用途，其中該醫藥組合物係選自由一有效劑量的一抗生素及一藥物可接受的鹽類所組成。
  2. 如申請專利範圍第1項所述之用途，其中該抗生素係選自由胺基配糖體抗生素、抗黴菌劑抗生素、頭孢子菌類抗生素、β-丙醯胺抗生素類、氯黴素抗生素、紅黴素類抗生素、青黴素類抗生素、四環素類抗生素及其他抗生素所組成群組之抗生素。
  3. 如申請專利範圍第2項所述之用途，其中該胺基配糖體抗生素係選自由Amikacin sulfate、Amikacin hydrate、Netilmicin Sulfate所組成之藥物。
  4. 如申請專利範圍第2項所述之用途，其中該抗黴菌劑抗生素係選自由Posaconazole、Artemisinin、Fluconazole、Ketoconazole、Voriconazole、Natamycin(Pimaricin)、Clotrimazole(Canesten)、Amphotericin B(Abelcet)、Flucytosine(Ancobon)、Amorolfine Hydrochloride、Terbinafine(Lamisil,Terbinex)、Butoconazole nitrate、Chloroxine、Bifonazole、Tioconazole、Nystatin(Mycostatin)、Miconazole nitrate、Liranaftate、Isoconazole nitrate(Travogen)、Terbinafine hydrochloride(Lamisil)、Ciclopirox ethanolamine、Caspofungin acetate、Naftifine HCl、Sertaconazole nitrate、Pyrithione zinc、Sulconazole Nitrate、Climbazole、Valnemulin HCl所組成之藥物。
  5. 如申請專利範圍第2項所述之用途，其中頭孢子菌類抗生素係選自由Cefdinir(Omnicef)、Cefoperazone(Cefobid)、Cefditoren pivoxil、Cephalexin(Cefalexin)、Cefoselis sulfate、Ceftiofur hydrochloride、Cefaclor(Ceclor)、Ceftazidime Pentahydrate、Moxalactam Disodium、Cephapirin Sodium所組成之藥物。
  6. 如申請專利範圍第2項所述之用途，其中β-丙醯胺抗生素係選自由Doripenem Hydrate、Meropenem、Aztreonam、Sulbactam、Sulbactam sodium(Unasyn)、Biapenem所組成之藥物。
  7. 如申請專利範圍第2項所述之用途，其中該氯黴素抗生素係選自由Gatifloxacin、Daptomycin、Sulfapyridine(Dagenan)、Sulfameter(Bayrena)、Chloramphenicol(Chloromycetin)所組成之藥物。
  8. 如申請專利範圍第2項所述之用途，其中該青黴素類抗生素係選自由Amoxicillin sodium(Amox)、Ampicillin sodium、Carbenicillin disodium、Dicloxacillin Sodium、Ampicillin Trihydrate、Benzylpenicillin sodium、Mezlocillin Sodium、Piperacillin Sodium所組成之藥物。
  9. 如申請專利範圍第2項所述之用途，其中該紅黴素類抗生素係選自由Teicoplanin、Linezolid(Zyvox)、Erythromycin(E-Mycin)、Erythromycin Ethylsuccinate、Spiramycin、Tilmicosin、Azithromycin Dihydrate、Dirithromycin、Fidaxomicin所組成之藥物。
  10. 如申請專利範圍第2項所述之用途，其中該四環素類抗生素係選自由Marbofloxacin、Moxifloxacin hydrochloride、Oxytetracycline(Terramycin)、Tigecycline、Oxytetracycline dihydrate、Tetracycline HCl、Chlortetracycline HCl、Minocycline HCl、Rolitetracycline所組成之藥物。
  11. 如申請專利範圍第2項所述之用途，其中該其他抗生素係選自由Norfloxacin(Norxacin)、Enoxacin(Penetrex)、Pefloxacin mesylate、Sparfloxacin、Levofloxacin(Levaquin)、Sarafloxacin HCl、Nalidixic acid(NegGram)、Lomefloxacin hydrochloride(Maxaquin)、Enrofloxacin、Clinafloxacin(PD127391)、Orbifloxacin、Clinafoxacin HCl、Piromidic Acid、Cinoxacin、Difloxacin HCl、Rifabutin(Mycobutin)、Rifapentine(Priftin)、Pyrazinamide(Pyrazinoic acid amide)、Rifampin(Rifadin,Rimactane)、Ethionamide、Rifaximin(Xifaxan)、Protionamide(Prothionamide)、Isoniazid(Tubizid)、D-Cycloserine、Streptomycin sulfate、Clofazimine、Nitrofurazone、Sulfanilamide、Sulfadiazine、Metronidazole(Flagyl)、Sulfamethoxazole、Sulfisoxazole、Sulfamethizole(Proklar)、Sulfadimethoxine、Clindamycin phosphate、Fenbendazole(Panacur)、Sulfadoxine(Sulphadoxine)、Secnidazole(Flagentyl)、Clindamycin palmitate HCl、Clindamycin、Sulfathiazole、Trimethoprim、Sulfamerazine、Pentamidine、Colistin Sulfate(polypeptide)、toltrazuril、tinidazoleMequinol、Bacitracin、Cetylpyridinium Chloride、Sulfaguanidine、Paromomycin Sulfate、Domiphen Bromide、Chlorquinaldol、Furaltadone HCl、Primaquine Diphosphate、Carbadox、Colistimethate Sodium、Meclocycline Sulfosalicylate、Thiostrepton、Bekanamycin、Clofoctol、Ritonavir、Entecavir hydrate、Artemisinin、Megestrol Acetate、Lansoprazole、Lopinavir(ABT-378)、Ondansetron hydrochloride、Resveratrol、Stavudine、Tenofovir Disoproxil Fumarate、Tenofovir(Viread)、Cidofovir(Vistide)、Telaprevir(VX-950)、Saxagliptin(BMS-477118,Onglyza)、Darunavir Ethanolate(Prezista)、Docosanol(Abreva)、Amprenavir(Agenerase)、Telbivudine(Sebivo,Tyzeka)、Hydrocortisone(Cortisol)、Didanosine(Videx)、Emtricitabine(Emtriva)、Lamivudine(Epivir)、Adefovir Dipivoxil(Preveon,Hepsera)、Zalcitabine、Prednisolone(Hydroretrocortine)、Nevirapine(Viramune)、Trifluridine(Viroptic)、Vidarabine(Vira-A)、Acyclovir(Aciclovir)、Albendazole Oxide(Ricobendazole)、Chenodeoxycholic acid、Valaciclovir HCl、Ganciclovir、Idoxuridine、Crystal violet、Rimantadine(Flumadine)、Taurine(organic acid)、Diclazuril(anticoccidial drug)、Rebamipide、Orphenadrine citrate(Norflex)、Terazosin HCl(Hytrin)、Lafutidine、Dextrose、BIBR-1048(Dabigatran)、Rosuvastatin calcium(Crestor)、Ammonium Glycyrrhizinate(AMGZ)、Amfebutamone(Bupropion)、Clonidine hydrochloride(Catapres)、Fluocinolone acetonide(Flucort-N)、Loperamide hydrochloride、Mycophenolic(Mycophenolate)、Olanzapine(Zyprexa)、Racecadotril(Acetorphan)、Rosiglitazone maleate、Salbutamol sulfate(Albuterol)、Tenoxicam(Mobiflex)、Vardenafil(Vivanza)、Dopamine hydrochloride(Inotropin)、Ritodrine hydrochloride(Yutopar)、Riboflavin(Vitamin B2)、Clomipramine hydrochloride (Anafranil)、Tiotropium Bromide hydrate、Isoprenaline hydrochloride、Medroxyprogesterone acetate、Xylometazoline HCl、Phenacetin、Trazodone hydrochloride(Desyrel)、Brompheniramine、Acemetacin(Emflex)、Dabrafenib(GSK2118436)、Paroxetine HCl、Zanamivir(Relenza)、Niflumic acid、Medetomidine HCl、Diclofenac Potassium、Ulipristal、Indacaterol Maleate、Biotin(Vitamin B7)、Sodium salicylate、Methylthiouracil、Darifenacin HBr、Benztropine mesylate、Abacavir sulfate、Antipyrine、Amitriptyline HCl、Azatadine dimaleate、Triflusal、Pemirolast(BMY 26517)potassium、Homatropine Bromide、Carbimazole、Spironolactone、Ropivacaine HCl、Escitalopram oxalate、Bismuth Subcitrate Potassium(mineral)、Chlorpropamide、Nifuroxazide、Penciclovir、Salicylanilide、Betamipron、Ethacridine lactate monohydrate(aromatic compound)、Aminothiazole、Florfenicol、Cetrimonium Bromide(antiseptic)、Thonzonium Bromide(detergent)、Pasiniazid所組成之藥物。
  12. 如申請專利範圍第1項所述之用途，其中該癌症係選自由肺癌、腸道癌、大腸直腸癌、前列腺癌、膀胱癌、子宮頸癌、乳癌及血癌所組成之群組。
TW104134908A 2014-10-24 2015-10-23 抗生素藥物臨床新應用 TWI672150B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24
US62/068,298 2014-10-24

Publications (2)

Publication Number Publication Date
TW201615217A true TW201615217A (zh) 2016-05-01
TWI672150B TWI672150B (zh) 2019-09-21

Family

ID=55760314

Family Applications (21)

Application Number Title Priority Date Filing Date
TW104134940A TW201615186A (zh) 2014-10-24 2015-10-23 脫克鈣藥物應用於癌症治療
TW104134950A TWI663969B (zh) 2014-10-24 2015-10-23 莫諾苯宗藥物應用於癌症治療
TW104134945A TW201615188A (zh) 2014-10-24 2015-10-23 奈必洛爾藥物應用於癌症治療
TW104134942A TW201615195A (zh) 2014-10-24 2015-10-23 阿那格雷藥物應用於癌症治療
TW104134965A TW201615226A (zh) 2014-10-24 2015-10-23 代謝性疾病藥物臨床新應用
TW104134960A TW201615191A (zh) 2014-10-24 2015-10-23 氨氯地平藥物應用於癌症治療
TW104134964A TW201615225A (zh) 2014-10-24 2015-10-23 內分泌疾病用藥臨床新應用
TW104134959A TW201615223A (zh) 2014-10-24 2015-10-23 驅蟲藥臨床新應用
TW104134928A TW201615197A (zh) 2014-10-24 2015-10-23 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療
TW104134963A TW201615224A (zh) 2014-10-24 2015-10-23 消化系統疾病用藥臨床新應用
TW104134956A TW201615196A (zh) 2014-10-24 2015-10-23 山喜多藥物應用於癌症治療
TW104134936A TWI621434B (zh) 2014-10-24 2015-10-23 千憂解藥物應用於癌症治療
TW104134961A TW201615193A (zh) 2014-10-24 2015-10-23 帕羅西汀藥物應用於癌症治療
TW104134954A TW201615222A (zh) 2014-10-24 2015-10-23 免疫疾病用藥臨床新應用
TW104134966A TW201615194A (zh) 2014-10-24 2015-10-23 氨苯蝶啶藥物應用於癌症治療
TW104134952A TW201615221A (zh) 2014-10-24 2015-10-23 炎症用藥臨床新應用
TW104134933A TWI652060B (zh) 2014-10-24 2015-10-23 阿折地平藥物應用於癌症治療
TW104134908A TWI672150B (zh) 2014-10-24 2015-10-23 抗生素藥物臨床新應用
TW104134944A TW201615219A (zh) 2014-10-24 2015-10-23 呼吸系統疾病用藥臨床新應用
TW104134924A TW201615218A (zh) 2014-10-24 2015-10-23 心血管疾病藥物臨床新應用
TW104134946A TWI663984B (zh) 2014-10-24 2015-10-23 神經疾病用藥臨床新應用

Family Applications Before (17)

Application Number Title Priority Date Filing Date
TW104134940A TW201615186A (zh) 2014-10-24 2015-10-23 脫克鈣藥物應用於癌症治療
TW104134950A TWI663969B (zh) 2014-10-24 2015-10-23 莫諾苯宗藥物應用於癌症治療
TW104134945A TW201615188A (zh) 2014-10-24 2015-10-23 奈必洛爾藥物應用於癌症治療
TW104134942A TW201615195A (zh) 2014-10-24 2015-10-23 阿那格雷藥物應用於癌症治療
TW104134965A TW201615226A (zh) 2014-10-24 2015-10-23 代謝性疾病藥物臨床新應用
TW104134960A TW201615191A (zh) 2014-10-24 2015-10-23 氨氯地平藥物應用於癌症治療
TW104134964A TW201615225A (zh) 2014-10-24 2015-10-23 內分泌疾病用藥臨床新應用
TW104134959A TW201615223A (zh) 2014-10-24 2015-10-23 驅蟲藥臨床新應用
TW104134928A TW201615197A (zh) 2014-10-24 2015-10-23 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療
TW104134963A TW201615224A (zh) 2014-10-24 2015-10-23 消化系統疾病用藥臨床新應用
TW104134956A TW201615196A (zh) 2014-10-24 2015-10-23 山喜多藥物應用於癌症治療
TW104134936A TWI621434B (zh) 2014-10-24 2015-10-23 千憂解藥物應用於癌症治療
TW104134961A TW201615193A (zh) 2014-10-24 2015-10-23 帕羅西汀藥物應用於癌症治療
TW104134954A TW201615222A (zh) 2014-10-24 2015-10-23 免疫疾病用藥臨床新應用
TW104134966A TW201615194A (zh) 2014-10-24 2015-10-23 氨苯蝶啶藥物應用於癌症治療
TW104134952A TW201615221A (zh) 2014-10-24 2015-10-23 炎症用藥臨床新應用
TW104134933A TWI652060B (zh) 2014-10-24 2015-10-23 阿折地平藥物應用於癌症治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW104134944A TW201615219A (zh) 2014-10-24 2015-10-23 呼吸系統疾病用藥臨床新應用
TW104134924A TW201615218A (zh) 2014-10-24 2015-10-23 心血管疾病藥物臨床新應用
TW104134946A TWI663984B (zh) 2014-10-24 2015-10-23 神經疾病用藥臨床新應用

Country Status (9)

Country Link
US (7) US10105357B2 (zh)
EP (3) EP3222278B1 (zh)
JP (1) JP6539345B2 (zh)
KR (1) KR102490334B1 (zh)
CN (3) CN107106523A (zh)
AU (2) AU2015335375B2 (zh)
ES (2) ES2954860T3 (zh)
TW (21) TW201615186A (zh)
WO (21) WO2016062271A1 (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1993360B1 (en) 2005-12-28 2017-02-08 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TW201615186A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 脫克鈣藥物應用於癌症治療
PT3236967T (pt) 2014-12-22 2020-01-06 Suda Pharmaceuticals Ltd Prevenção e tratamento de doença metastática em pacientes com cancro trombocitóticos
WO2017116049A1 (ko) * 2015-12-31 2017-07-06 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (zh) * 2016-06-15 2016-11-09 中南大学湘雅医院 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用
WO2018072135A1 (zh) 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 二氢吡啶类钙拮抗剂用于治疗癌症的用途
CN108066345A (zh) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 一种具有抗肿瘤作用的化合物
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
RU2764443C2 (ru) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен
US12233073B2 (en) 2017-06-09 2025-02-25 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
US20200129492A1 (en) * 2017-07-03 2020-04-30 Menri Group Ltd. Treatment of cancer with dihydropyridines
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
KR101933805B1 (ko) 2017-10-17 2018-12-28 성균관대학교산학협력단 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물
CN108186652A (zh) * 2017-12-28 2018-06-22 深圳大学 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用
CN118384147A (zh) 2018-01-30 2024-07-26 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
MX2020014286A (es) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
FR3090084B1 (fr) 2018-12-18 2023-10-13 Securengy Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent.
WO2020132253A1 (en) * 2018-12-19 2020-06-25 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
EP3949959A4 (en) * 2019-04-04 2022-05-11 Daegu-Gyeongbuk Medical Innovation Foundation PHARMACEUTICAL COMPOSITION COMPRISING TRIMEBUTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USED AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
WO2020206078A1 (en) * 2019-04-05 2020-10-08 University Of North Texas Health Science Center At Fort Worth Antidepressants for the treatment or prevention of memory loss and/or cognitive decline or dysfunction in aging
US20220146492A1 (en) * 2019-04-11 2022-05-12 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (zh) * 2019-05-31 2019-08-30 天津科技大学 一种噻吨溴类化合物的应用
EP3797773A1 (en) * 2019-09-03 2021-03-31 Square Power Ltd Rebamipide for use in prophylaxis and treatment of cancer
CN110742890A (zh) * 2019-10-24 2020-02-04 暨南大学 洛美利嗪在制备抗结肠癌药物中的应用
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN110840887A (zh) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 三氯苯达唑在制备治疗乳腺癌的药物中的应用
CN111067899B (zh) * 2020-01-08 2021-03-05 温州医科大学 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (zh) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途
CN111557941A (zh) * 2020-06-15 2020-08-21 浙江大学 Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用
CN111848717A (zh) * 2020-08-07 2020-10-30 四川大学 靶向调控线粒体能量代谢的化合物及其应用和药物
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN112336725A (zh) * 2020-12-11 2021-02-09 吴照球 甲氧苄啶的医药新用途
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN112569215A (zh) * 2020-12-30 2021-03-30 东莞市人民医院 度米芬在制备防治结直肠癌的药物中的应用
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (zh) * 2021-06-28 2022-12-30 四川大学 Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (zh) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 五氟利多在制备治疗子宫内膜癌的药物中的应用
CN115887455B (zh) * 2022-08-04 2024-04-05 北京大学人民医院 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用
CN115778957B (zh) * 2022-11-04 2024-06-21 天津中医药大学 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用
CN116850266A (zh) * 2023-06-02 2023-10-10 大连理工大学 多粘菌素e甲磺酸钠在制备治疗三阴性乳腺癌药物中的应用
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用
CN118059099B (zh) * 2024-04-19 2024-06-14 四川大学华西医院 帕罗西汀联合asct2抑制剂用于制备治疗肝癌的药物中的应用及药物组合物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG55007A1 (en) * 1993-10-01 1998-12-21 Syntrex U S A Inc Mycophenolate mofetil high dose oral suspensions
NZ298074A (en) * 1994-12-28 2001-01-26 Janssen Pharmaceutica Nv Use of alpha,alpha'-iminobis(methylene)bis[2-chromanmethanol] derivatives for treating degenerative diseases of the vascular or nervous systems
ATE449603T1 (de) * 1998-09-15 2009-12-15 Lilly Co Eli Verwendung von duloxetine zur behandlung von fibromyalgie
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
CN1690047B (zh) * 2000-07-07 2010-10-06 塔夫茨大学信托人 9-取代的二甲胺四环素化合物
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005027842A2 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
BRPI0416275A (pt) * 2003-11-06 2007-01-23 Celgene Corp métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
WO2005115388A1 (en) * 2004-05-12 2005-12-08 Biorunx Co., Ltd. A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer
HUE030212T2 (en) * 2004-05-21 2017-04-28 Harvard College Synthesis of tetracyclines and their analogues
CN1279980C (zh) * 2004-10-14 2006-10-18 孔庆忠 一种抗实体肿瘤药物组合物
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (zh) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 制备缬沙坦的方法
CA2615710C (en) * 2005-07-28 2017-09-12 Color Foundation (Stichting Color) Sensitization of immune system against haptenized melanoma antigens
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
JP5309014B2 (ja) * 2006-03-23 2013-10-09 アムジエン・インコーポレーテツド シナカルセットの多形体の製造および使用のための方法および組成物
CN101099724A (zh) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 一种微粉化来曲唑及其组合物
CN101103976A (zh) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 一种含阿那曲唑的口服药物组合物及其制备工艺
EP2114399A2 (en) * 2007-01-05 2009-11-11 Cornerstone Therapeutics Inc. R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
EP2170805B1 (en) * 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
US20090054312A1 (en) * 2007-08-22 2009-02-26 Wolf Dieter A SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (zh) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂
WO2009126274A2 (en) * 2008-04-08 2009-10-15 New York University School Of Medicine Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (zh) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 氨氯地平在制备治疗细胞增生性疾病药物中的用途
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN101991553B (zh) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 一种依西美坦片及其制备方法
CN101863806B (zh) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 抗前列腺癌药物(r)-比卡鲁胺的制备方法
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
JP5978424B2 (ja) * 2010-07-29 2016-08-24 国立大学法人京都大学 抗がん剤のスクリーニング方法
WO2012079232A1 (zh) * 2010-12-15 2012-06-21 Lai Hung-Cheng 用于治疗癌症的化合物及其应用
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
CN102688493B (zh) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN102813643B (zh) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 bumetanide在抑制肝癌细胞转移中的应用
CN103930132A (zh) * 2011-09-27 2014-07-16 拜奥迈德瓦利探索有限公司 治疗胶质瘤的组合物和方法
AU2012335009B2 (en) * 2011-11-10 2017-08-31 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
CN102600077B (zh) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 吉西他滨或其盐纳米乳剂注射液及其制备方法
ES2384069B1 (es) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet y tumores neuroblásticos
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
US20150224169A1 (en) * 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
BR112015006176B1 (pt) * 2012-09-21 2023-04-18 Intensity Therapeutics, Inc Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
TWI609686B (zh) * 2012-10-04 2018-01-01 Ａｂ科學公司 使用馬賽替尼治療以預測因子所識別的癌症患者亞群
CN102872066B (zh) * 2012-10-19 2014-07-02 厦门大学 伊维菌素及其衍生物的用途
CA3159085A1 (en) * 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
US9890127B2 (en) * 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (zh) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 阿那格雷及其衍生物的抗肿瘤用途
CN103396419A (zh) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法
CN103536925B (zh) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN103622975B (zh) * 2013-11-07 2016-06-15 广东药学院 格列吡嗪在制备治疗肿瘤药物中的应用
WO2015157471A1 (en) * 2014-04-08 2015-10-15 The Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics
TW201615186A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 脫克鈣藥物應用於癌症治療

Also Published As

Publication number Publication date
WO2016062272A1 (zh) 2016-04-28
WO2016062266A1 (zh) 2016-04-28
WO2016062285A1 (zh) 2016-04-28
US10045962B2 (en) 2018-08-14
WO2016062288A1 (zh) 2016-04-28
ES2954860T3 (es) 2023-11-27
WO2016062289A1 (zh) 2016-04-28
WO2016062278A1 (zh) 2016-04-28
TW201615197A (zh) 2016-05-01
EP3235497A4 (en) 2018-06-13
CN107106550A (zh) 2017-08-29
TWI621434B (zh) 2018-04-21
US20170304388A1 (en) 2017-10-26
CN106999470A (zh) 2017-08-01
EP3210604B1 (en) 2024-02-14
TW201615224A (zh) 2016-05-01
TWI663969B (zh) 2019-07-01
TW201615218A (zh) 2016-05-01
EP3222278C0 (en) 2023-06-14
EP3210604A1 (en) 2017-08-30
WO2016062279A1 (zh) 2016-04-28
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
TWI672150B (zh) 2019-09-21
WO2016062267A1 (zh) 2016-04-28
TWI663984B (zh) 2019-07-01
CN107106523A (zh) 2017-08-29
JP6539345B2 (ja) 2019-07-03
TW201615184A (zh) 2016-05-01
WO2016062281A1 (zh) 2016-04-28
TW201615221A (zh) 2016-05-01
WO2016062277A1 (zh) 2016-04-28
AU2015335391A1 (en) 2017-06-01
AU2015335375B2 (en) 2020-09-10
US20170304218A1 (en) 2017-10-26
TW201615220A (zh) 2016-05-01
EP3235497A1 (en) 2017-10-25
WO2016062265A1 (zh) 2016-04-28
KR20170084034A (ko) 2017-07-19
TW201615196A (zh) 2016-05-01
AU2015335375A1 (en) 2017-05-18
TW201615192A (zh) 2016-05-01
WO2016062274A1 (zh) 2016-04-28
EP3210604A4 (en) 2018-06-27
EP3222278A1 (en) 2017-09-27
TW201615186A (zh) 2016-05-01
TW201615193A (zh) 2016-05-01
US20170312260A1 (en) 2017-11-02
ES2973279T3 (es) 2024-06-19
US20170304286A1 (en) 2017-10-26
TW201615194A (zh) 2016-05-01
WO2016062291A1 (zh) 2016-04-28
US20170216247A1 (en) 2017-08-03
JP2017532351A (ja) 2017-11-02
WO2016062275A1 (zh) 2016-04-28
TW201615195A (zh) 2016-05-01
WO2016062283A1 (zh) 2016-04-28
TW201615222A (zh) 2016-05-01
WO2016062286A1 (zh) 2016-04-28
WO2016062269A1 (zh) 2016-04-28
EP3222278A4 (en) 2018-06-20
WO2016062270A1 (zh) 2016-04-28
US10098852B2 (en) 2018-10-16
US20170304387A1 (en) 2017-10-26
TWI652060B (zh) 2019-03-01
AU2015335391B2 (en) 2018-06-21
TW201615219A (zh) 2016-05-01
EP3210604C0 (en) 2024-02-14
TW201615189A (zh) 2016-05-01
TW201615226A (zh) 2016-05-01
WO2016062290A1 (zh) 2016-04-28
TW201615191A (zh) 2016-05-01
TW201615188A (zh) 2016-05-01
EP3222278B1 (en) 2023-06-14
KR102490334B1 (ko) 2023-01-18
WO2016062287A1 (zh) 2016-04-28
TW201615225A (zh) 2016-05-01
TW201615223A (zh) 2016-05-01
WO2016062271A1 (zh) 2016-04-28

Similar Documents

Publication Publication Date Title
TWI672150B (zh) 抗生素藥物臨床新應用
EP2802209B1 (en) Otic formulations
RU2675360C2 (ru) Способы лечения местных микробных инфекций
EP2953624B1 (en) Methods of treating microbial infections, including mastitis
ES2972618T3 (es) Composición antibacteriana de combinación y régimen antibacteriano de corta duración que comprende linezolid, bedaquilina y pretomanida
US11446353B2 (en) Compositions and methods for the treatment of fungal infections
JP2007332141A (ja) 薬
US20170027951A1 (en) Methods and compositions to treat cancers involving egfr
JP2011514902A (ja) 抗感染剤の安定な液体配合物および調節した抗感染剤投与計画
Hubka et al. In vitro susceptibility of canine and feline Escherichia coli to fosfomycin
AU2018368453B2 (en) Cancer therapy by degrading dual MEK signaling
Reyns et al. Disposition and oral bioavailability of amoxicillin and clavulanic acid in pigs
TWI725948B (zh) 有效對抗包括抗藥性微生物類之微生物群的組合治療
US20180064710A1 (en) Antifungal treatment of psoriasis
TWI826738B (zh) 癌症治療方法
US20080139545A1 (en) Formulation to treat ear infection
TW200403072A (en) Combination therapy for the treatment of bacterial infections
US9849126B2 (en) Sterile otic formulations
Rasmussen et al. Penicillin concentrations in bone and subcutaneous tissue: A porcine microdialysis study comparing oral and intravenous treatment
WO2019004466A1 (ja) 医薬
BR112021004523A2 (pt) formulações para liberação sustentada em dispositivos de administração
WO2023212291A1 (en) Treatment of pathogenic neisseria sp. infection with triazole antifungal agents
Abugaa et al. Supplementary info: Quality control results of drugs analyzed in DARU during the period 2016-2020
Seifert et al. Drugs for the Treatment of Bacterial Infections
Schriever et al. Antimicrobial Agents

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees